ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 151 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $15,381,000 | +48.0% | 459,134 | +17.5% | 0.00% | 0.0% |
Q3 2016 | $10,396,000 | +25.3% | 390,688 | +3.8% | 0.00% | +100.0% |
Q2 2016 | $8,296,000 | -24.5% | 376,248 | +0.5% | 0.00% | -50.0% |
Q1 2016 | $10,990,000 | -11.1% | 374,196 | -0.0% | 0.00% | 0.0% |
Q4 2015 | $12,360,000 | -13.5% | 374,316 | -5.4% | 0.00% | 0.0% |
Q3 2015 | $14,296,000 | -10.5% | 395,583 | +11.5% | 0.00% | -33.3% |
Q2 2015 | $15,967,000 | +60.6% | 354,891 | +9.3% | 0.00% | +50.0% |
Q1 2015 | $9,941,000 | +15.8% | 324,645 | +92.3% | 0.00% | +100.0% |
Q4 2014 | $8,586,000 | +42.2% | 168,859 | +10.7% | 0.00% | 0.0% |
Q3 2014 | $6,036,000 | +20.6% | 152,550 | +31.3% | 0.00% | 0.0% |
Q2 2014 | $5,003,000 | +210.7% | 116,164 | +188.6% | 0.00% | – |
Q1 2014 | $1,610,000 | +11.3% | 40,249 | -24.0% | 0.00% | – |
Q4 2013 | $1,446,000 | -23.0% | 52,991 | -35.3% | 0.00% | – |
Q3 2013 | $1,878,000 | -42.3% | 81,926 | -55.4% | 0.00% | -100.0% |
Q2 2013 | $3,252,000 | – | 183,633 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |